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There was an increase in the Clostridium difﬁcile infection (CDI) rate in our bone marrow transplantation unit.
To evaluate the role of unit-based transmission, C. difﬁcile screening was performed on adult patients
admitted for hematopoietic stem cell transplantation (HSCT) over a 2-year period, and C. difﬁcile isolates were
typed. C. difﬁcile testing was performed using a 2-step C. difﬁcile glutamate dehydrogenase antigen plus toxin
A/B enzyme immunoassay (EIA) and cytotoxin assay (or molecular toxin assay). Multilocus sequence typing
(MLST) was performed on toxin-positive whole stool samples. A retrospective chart review was performed on
all patients with a positive toxin assay. Sixteen of 150 patients (10.7%) had toxigenic C. difﬁcile colonization
(CDC) on admission. The overall incidence of CDI within 100 days after HSCT was 24.7% (37 of 150). The
median time to diagnosis of CDI was 3.5 days after HSCT. In an adjusted logistic regression model, CDC on
admission was a signiﬁcant risk factor for CDI (odds ratio, 68.5; 95% conﬁdence interval, 11.4 to 416.2). MLST
on 22 unit patient toxin-positive stool specimens revealed 15 distinct strain types. Further analysis identiﬁed
at least 1 potential cross-transmission event; some events may have been missed because of incomplete
typing from other specimens. Despite aggressive infection control interventions, there was no decline in the
number of CDI cases during the study period. These data suggest that prior CDC plays a major role in CDI rates
in this high-risk patient population. It remains unclear if CDI was cross-transmitted in the unit.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION long-term care facilities [5]. Some investigators have sug-
Clostridium difﬁcile infection (CDI) is the most common
infectious cause of health careeassociated diarrhea [1]. CDI
rates in hematopoietic stem cell transplantation (HSCT) re-
cipients are up to 9-fold higher than those in other inpatients
[2]. Some studies have reported that HSCT recipients who
acquired CDI experience higher rates of morbidity and
mortality [3,4].
Although symptoms of CDI usually begin soon after
colonization, 50% or more of hospitalized patients who are
colonized with C. difﬁcile are asymptomatic carriers [5]. The
prevalence of asymptomatic colonization with C. difﬁcile
(CDC) ranges from 7% to 26% among adult inpatients in acute
care facilities and from 5% to 7% among elderly patients indgments on page 1334.
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14.04.026gested that asymptomatic CDC could play a role in CDI in
patients admitted for a HSCT [6]. However, the prevalence of
CDC in HSCT recipients is not known.
An increase in CDI rates was noted over a 2-year period in
our bone marrow transplantation (BMT) unit, during which
time hospital-wide CDI rates remained stable. In particular,
some CDI cases appeared to cluster together in certain
months, raising a concern for unit-based transmission of
C. difﬁcile. To investigate the role of cross-transmission, a
screening protocol for asymptomatic CDC on admission was
implemented, patients were monitored closely for CDI, and
toxin-positive stool specimens were saved for molecular
typing. At the same time, enhanced infection control in-
terventions were implemented.
MATERIALS AND METHODS
Patients
The study population comprised all patients who were admitted to the
BMT unit for an HSCT from January 2011 to December 2012 at ThomasTransplantation.
Table 1
Demographic Data, Diagnoses, and Transplantation Types for All Patients
Admitted for Hematopoietic Stem Cell Transplantation (n ¼ 150)
Characteristics n (%)
Age, mean  SD, yr 53  13.4
Male 92 (61.3)
Diagnosis
Acute lymphoblastic leukemia 14 (9.3)
Acute myeloid leukemia 31 (20.7)
Multiple myeloma 53 (35.3)
Lymphoma 25 (16.7)
Myelodysplastic syndrome 15 (10.0)
Chronic lymphocytic leukemia 4 (2.7)
Myeloproliferative disorders including chronic
myeloid leukemia
4 (2.7)
Other* 4 (2.7)
Transplantation type
Autologous 58 (38.7)
Allogeneic 92 (61.3)
Haploidentical 67 (72.8)
Matched related 15 (16.3)
Unrelated 9 (9.8)
Syngeneic 1 (1.1)
Myeloablative conditioning regimen 59 (64.1)
* Other diagnoses: amyloidosis (2), aplastic anemia (1), sickle cell ane-
mia (1)
J. Bruminhent et al. / Biol Blood Marrow Transplant 20 (2014) 1329e13341330Jefferson University Hospital, a tertiary care, academic medical center in
Philadelphia, Pennsylvania. The study was approved by the institutional
review board of Thomas Jefferson University.
C. difﬁcile Testing
First stool samples collected after admissionwere testedwith a standard
2-step assay; in some cases, collection occurred beyond the ﬁrst 48 hours of
admission. Specimens were tested with a rapid enzyme immunoassay (EIA)
for glutamate dehydrogenase antigen and toxins A and B (Wampole C Diff
Quik Chek Complete, Techlab, Inc., Blacksburg, VA). A tissue culture cyto-
toxin assay was then performed on antigen-positive, rapid toxinenegative
specimens during 2011. In 2012, the second-step cytotoxin assay was
replaced with a molecular assay (Illumigene C. difﬁcile, Meridian Bioscience,
Inc., Cincinnati, OH). EIA-negative samples were not further tested. Patients
who developed symptoms concerning for CDI were tested with the same 2-
step assay, as per standard of care. Aliquots of all toxin-positive stool sam-
ples were saved in a 20C freezer for subsequent typing.
C. difﬁcile Typing
C. difﬁcile typing was performed on DNA extracted from frozen whole
stool specimens. First, 100 uL of thawed stool was mixed with 400 uL of
S.T.A.R. Buffer (Gen-Probe Prodesse Inc.,Waukesha,WI) in a 1.5mLmicrofuge
tube. This mixture was vortexed for 15 seconds, centrifuged for 1 minute at
15,000 g, and the supernatant was stored at 4C for up to 7 days. A 100 uL
aliquot of each specimenwas loaded into the NucliSENS easyMAG automated
nucleic acid extraction system (bioMérieux, Durham, NC) using the manu-
facturer’s generic protocol, and the eluted total nucleic acid was stored
at 20C until time of testing.
Multilocus sequence typing (MLST) was performed as described in
Grifﬁths et al. using the same primers, cycling parameters, and similar
conditions for polymerase chain reaction ampliﬁcation and sequencing of 7
housekeeping genes (adk, atpA, dxr, glyA, recA, soda, and tpi) [7]. Each
housekeeping gene was separately ampliﬁed using AmpliTaq Gold poly-
merase (Applied Biosystems, Branchburg, NJ) and sequenced using BigDye
Ready Reaction Mix (Applied Biosystems). For each sample, the individual
MLST sequences obtained from a 3130 XL Genetic analyzer (Applied Bio-
systems) were evaluated with the Applied Biosystems Sequencing Analysis
5.2.0 software and entered into the database query on http://pubmlst.org/
cdifﬁcile. Alleles were determined for each housekeeping gene based on the
speciﬁc sequences of each sample, and a strain type was assigned.
HSCT Protocols
All patients received pneumocystis, fungal, and herpes simplex pro-
phylaxis, but antibacterial prophylaxis with quinolones was not given. Pa-
tients were treated with broad-spectrum intravenous antibiotics for
neutropenic fever per standard of care; intravenous ceftazidime was the
ﬁrst-line therapy.
The BMT program performs both autologous and allogeneic HSCTs on
adult patients. The program specializes in performing haploidentical HSCTs
using a 2-step protocol: patients initially receive a conditioning regimen
followed by a donor lymphocyte infusion (DLI), followed by cyclophospha-
mide, and then an infusion of CD34þ hematopoietic progenitor cells is
administered several days later [8]. These DLIs frequently result in a tran-
sient systemic inﬂammatory response syndrome, which typically consists of
high fevers, chills, hypotension, and diarrhea.
Infection Control Practices
During the study period, all patients admitted to the BMT unit were
placed on contact precautions, all rooms were cleaned daily with bleach-
containing wipes, and hand hygiene with soap and water (no alcohol
hand rub) was mandated upon exiting all rooms. All rooms were cleaned
with bleach when patients were discharged.
Chart Review and Deﬁnitions
An electronic medical record reviewwas performed on all patients with
C. difﬁcile toxinepositive stool specimens to collect clinical data, including
room locations, medications, bowel movement numbers and consistency,
and pertinent lab data. CDC was deﬁned as the absence of diarrhea and
either a positive C. difﬁcile toxin EIA or cytotoxin assay or toxin PCR assay.
CDI was deﬁned as the presence of diarrhea (3 or more loose stools within
24 hours), a stool test positive for C. difﬁcile toxin, and administration of
speciﬁc C. difﬁcile treatment (oral vancomycin, oral metronidazole, or
intravenous metronidazole). Relapsewas deﬁned as a second episode of CDI
occurring within 2 to 8 weeks of the ﬁrst episode [9].
Statistical Analyses
Continuous data were summarized by the mean  standard deviation.
Categorical data were summarized by frequencies and percentages. Foranalyses between patients with and without CDC, the chi-square test or
Fisher exact testwas used for comparing groups by categorical variables, and
Student t-test or Wilcoxon’s rank-sum test was used for comparing groups
by continuous variables.
Multivariate analysis was performed using multiple logistic regression
of the odds of CDI. A backward stepwise variable selection routine was used
to select predictors from a set of variables including age, gender, CDC on
admission, prior admission within the last 90 days, prior CDI within last
6 months, allogeneic transplantation, graft-versus-host disease (GVHD),
interaction of allogeneic and GVHD, myeloablative versus nonmyeloablative
conditioning regimen, interaction of allogeneic and conditioning regimen, a
pre-post indicator based on a time-point where it appears the rate of CDI
increased (ie, January 1, 2012), a numeric time variable corresponding to day
of admission centered at January 1, 2012, and an interaction between time
and pre-post indicator. Because there were only 37 incident CDI cases, the
selection was limited to the 4 most important predictor variables by setting
the exclusion criterion to .15.
A 2-tailed P value of less than .05 was considered to be statistically
signiﬁcant for hypothesis testing. Statistical analyses were performed using
statistical software (SAS version 9.3, SAS Institute, Cary, NC).RESULTS
Patient Characteristics
A total of 150 adult patients were admitted for HSCT
during the 2-year study period. Overall patient characteris-
tics are shown in Table 1. Fifty-eight (38.7%) patients received
autologous stem cell transplantations, primarily performed
for a diagnosis of multiple myeloma (91.4%). The allogeneic
HSCT group of 92 (61.3%) patients comprised a more het-
erogeneous patient population with a variety of hemato-
logical malignancies. The majority of allogeneic HSCT
recipients received haploidentical transplantation (67 of 92,
72.8%) and underwent a myeloablative conditioning regimen
(59 of 92, 64.1%).Analysis of Patients with CDC
Out of 150 patients admitted for a HSCT, 16 patients
(10.7%) had toxigenic CDC. C. difﬁcile toxin was detected in
admission stool samples by EIA in 6 cases, cytotoxin assay in
4 cases, and molecular assay in 6 cases. Nine of 16 (56.3%)
toxin-positive patients had been hospitalized within the
previous 90 days. Only 1 of 16 (6.3%) CDC patients had a
documented prior CDI within 6 months.
Table 3
Comparison of Demographic and Transplantation Data and Outcomes for
Patients with or without Clostridium Difﬁcile Infection (CDI) within 100 Days
after Hematopoietic Stem Cell Transplantation
CDI
(37 cases)
(n, %)
No CDI
(113 Cases)
(n, %)
P Value
Age (mean  SD), yr 47.6  16.2 54.1  12.1 .03
Male 23 (62.2) 69 (61.1) 1.00
Clostridium difﬁcile
colonization
14 (37.8) 2 (1.8) <.01
Prior CDI within 6 mo 1 (2.7) 5 (4.4) 1.00
Prior admission within 90 d 19 (51.4) 50 (44.3) .575
Transplantation type
Autologous HSCT 14 (37.8) 44 (38.9) 1.00
Age (autologous group) 51.6  16.6 54.8  11.8 .53
Allogeneic HSCT 23 (62.2) 69 (61.1) .91
Age (allogeneic group) 45.1  15.8 53.8  12.3 .02
Haploidentical 16 of 23 (69.6) 51 of 69 (73.9) .04
Matched sibling 6 of 23 (26.1) 9 of 69 (13)
Unrelated donor 0 of 23 (0) 9 of 69 (13)
Syngeneic 1 of 23 (4.3) 0 of 69 (0)
Myeloablative regimen 13 of 23 (56.5) 46 of 69 (66.7) .45
GVHD within 100 d after
HSCT
8 of 23 (34.8) 32 of 69 (46.4) .47
Gastrointestinal GVHD 3 of 23 (13.0) 8 of 69 (11.6) 1.00
Skin GVHD 5 of 23 (21.7) 25 of 69 (36.2) .30
Length of stay (mean  SD), d 35  26 32  22 .51
Mortality within 100 days
after HSCT
4 (10.8) 7 (6.2) .47
CDI indicates Clostridium difﬁcile infection; HSCT, hematopoietic stem cell
transplantation; GVHD, graft-versus-host disease.
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CDC and non-CDC patients is shown in Table 2. There was no
difference in CDC rates between patients scheduled to un-
dergo autologous versus allogeneic HSCTs. However, CDC
patients were signiﬁcantly younger than the noncolonized
patients; this difference was primarily related to the younger
age of CDC patients within the allogeneic group. There were
no apparent differences in the underlying diseases (data not
shown) or transplantation types among the CDC and non-
CDC patients in the allogeneic group.
Analysis of Patients with CDI
The overall incidence of CDI within 100 days after HSCT
was 24.7% (37 of 150). Fourteen of 16 patients (87.5%) with
CDC developed CDI; all cases occurred during the HSCT
admission. Among the 134 patients with negative screens, 23
(17.2%) developed CDI: 20 patients developed CDI during the
index admission (hospital-onset CDI), and 3 patients were
readmitted with CDI within 30 days of discharge.
A comparison of patients with and without CDI is shown
in Table 3. The mean age of patients with CDI was signiﬁ-
cantly lower than patients without CDI, primarily because of
the younger age of CDI patients among the allogeneic group.
CDCwas amajor risk factor for CDI (14 of 16 versus 23 of 134;
P < .01). The incidence of CDI was similar between autolo-
gous and allogeneic HSCT recipients (24.1% versus 25%,
respectively). There were no signiﬁcant differences in the
diseases among the allogeneic recipients with and without
CDI (data not shown). The likelihood of CDI was not homo-
geneous across transplantation types among allogeneic
recipients (P ¼ .04).
Onset of CDI
CDI was diagnosed on mean hospital day 10.7  5.2 and a
mean of 3.6  16.3 days after HSCT (day after infusion of the
CD34þ-selected or unselected stem cell product) (median,
3.5 days). There was no signiﬁcant difference in the timing of
CDI between the autologous and allogeneic HSCT recipients
(data not shown). However, CDI occurred signiﬁcantly earlier
in CDC patients compared with non-CDC patients (mean
hospital day 9 3 versus 13 7, P¼ .01; mean day after HSCT
0  5 versus 11  9, P < .001). The time interval between
initiation of intravenous antibiotic therapy to the onset ofTable 2
Comparison of Demographic and Transplantation Data for Patients
Admitted for HSCT with or without Toxigenic Clostridium Difﬁcile Coloni-
zation (CDC)
CDC Positive
(16 Cases)
(n, %)
CDC Negative
(134 Cases)
(n, %)
P
Value
Age, mean  SD, yr 39.8  16.9 54.1  12.2 <.01
Male 10 (62.5) 82 (61.2) 1.00
Prior CDI within 6 mo 1 (6.25) 5 (3.7) .50
Previous admission within 90 d 9 (56.3) 60 (44.8) .43
Type of transplantation
Autologous 5 (31.3) 53 (39.6) .60
Age (mean  SD), yr 45.4  21.3 54.8  12.0 .38
Allogeneic 11 (68.7) 81 (60.4)
Age (mean  SD), yr 37.2  14.9 53.5  12.4 <.01
Haploidentical 9 of 11 (81.8) 58 of 81 (71.6) .89
Matched sibling 1 of 11 (9.1) 14 of 81 (17.3)
Unrelated donor 1 of 11 (9.1) 8 of 81 (9.9)
Syngeneic 0 of 11 (0) 1 of 81 (1.2)
Myeloablative regimen 9 of 11 (81.8) 50 of 81 (61.7) .32
HSCT indicates hematopoietic stem cell transplantation; CDC, Clostridium
difﬁcile colonization; CDI, Clostridium difﬁcile infection.CDI was also shorter in CDC patients compared with non-
CDC patients (mean, day 0 versus 4) but was not quite sta-
tistically signiﬁcant (P ¼ .06).
Distribution of CDC and CDI Cases during the Study
Period
A total of 42 patients were diagnosed with CDI on the
BMT unit during the study period, including 5 CDI cases that
occurred in patients who underwent HSCT before the study
and were readmitted to the BMT unit. As shown in Figure 1,
the overall number of CDI cases and types of CDI per quarter
varied over the 2-year study period (2011 and 2012). The
number of CDC cases peaked in the ﬁrst quarter of 2012. The
rates of health careeassociated CDI per 10,000 patient days
on the BMT unit are shown in Figure 2; this analysis uses
established surveillance deﬁnitions for health care-
eassociated CDI, regardless of CDC status [5]. Of note, there
was a cluster of hospital onset cases in the third quarter of
2012, suggesting possible cross-transmission.
Outcomes of CDI Cases
All patients with CDI were treated with either oral
metronidazole or oral vancomycin (with or without i.v.
metronidazole) for a minimum of 10 days. In some cases,
patients were continued on treatment beyond 14 days if they
were still on broad-spectrum intravenous antibiotics. None
of the CDI patients required colectomy or had a CDI-related
mortality. There was no difference in length of stay or over-
all mortality within 100 days after HSCT between patients
with and without CDI (Table 3). Only 3 of 37 patients with
CDI (8.1%) experienced recurrent CDI within 100 days after
HSCT: 2 patients had a relapse within 8 weeks after initial
diagnosis and 1 patient had another episode of CDI at
10 weeks. None of the recurrences occurred in the CDC
patients.
Figure 1. Number of Clostridium difﬁcile infection (CDI) cases in the bone
marrow transplantation unit and the strain types identiﬁed in each quarter
(qtr) over the 2-year study period. The strain types are listed above the
appropriate bars. Two additional strains (types 16 and 34) were identiﬁed on
admission screens from patients who did not develop CDI in qtr 3 2011 and qtr
4 2012. CDC > CDI indicates recipients with Clostridium difﬁcile colonization
(CDC) who developed CDI during admission; hospital-onset CDI, recipients
without CDC who developed CDI during admission; community-onset CDI
within 4 weeks after discharge, recipients readmitted with CDI within
4 weeks; relapse, patients who developed a second episode of CDI within
8 weeks; other CDI cases, patients who underwent hematopoietic stem cell
transplantation before the study period and developed CDI upon readmission
during the study period.
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Among the allogeneic HSCT recipients, the overall rate of
GVHDwithin 100 days after HSCTwas 43.4% (40 of 92). There
were no signiﬁcant differences in rates of gastrointestinal or
skin GVHD between CDC and non-CDC patients (data not
shown) or patients with and without CDI (Table 3).
CDI Modeling
The variables selected for the multiple logistic regression
model were CDC, time, pre-post indicator (before versus af-
ter January 1, 2012), and a time-by-pre-post interaction. CDC
appeared to increase the odds of CDI by 69-fold (odds ratio,
68.51; 95% conﬁdence interval, 11.28 to 416.17). Over theFigure 2. Quarterly rates of health careeassociated Clostridium difﬁcile infec-
tion (CDI) in the bone marrow transplantation unit (regardless of C. difﬁcile
colonization status). Rates are calculated as number of CDI cases per 10,000
patient days, based on surveillance deﬁnitions for health careeassociated CDI
[5]. This ﬁgure includes all hospital-onset CDI cases and community-onset
cases within 4 weeks after discharge, regardless of colonization status. Other
patients with CDI present on admission are excluded.course of the study, the odds of CDI signiﬁcantly changed
around the beginning of 2012. The odds of CDI were
decreasing with time in the pre-January 1, 2012 period, but
the odds of CDI began to slightly increase with time in the
post-January 1, 2012 period.
C. difﬁcile Strains
MLST on C. difﬁcile toxinepositive stool specimens from
22 BMT unit patients revealed 15 distinct types (Figure 3).
Strain type 2 was the most common type identiﬁed (27.3%).
All of the cases with the same strains (types 2, 4, and 42)
occurred more than 3 months apart, except 2 pairs of pa-
tients with strain type 2. In 1 pair, patients were admitted
5 days apart with positive C. difﬁcile screens for strain type 2;
thus, both patients were already colonized. In the other pair,
patients with negative admission screens developed CDI
with strain type 2 less than 3 weeks apart in the third quarter
of 2012. This represents a possible cross-transmission event.
Additionally, in the third quarter of 2012, there was a cluster
of 3 patients who acquired CDI in the same room in the BMT
unit but had 3 distinct strain types [10]. Of note, the NAP 1
epidemic strain (strain type 1), which has unique sequence
features and is associated with an increased severity of CDI,
was present in only 1 of 22 patients (4.5%) [11,12]. Typing on
20 other toxin-positive stool specimens from BMT unit pa-
tients was not available: 11 specimens were not saved, MLST
PCR reactions were negative on 3 specimens, and sequencing
results were incomplete on 6 specimens.
MLST on 39 toxin-positive specimens from non-BMT unit
patients during this same time period identiﬁed 18 different
C. difﬁcile strain types (Figure 3). In contrast with the BMT
unit, the epidemic strain type 1 was the predominant strain
(18%) identiﬁed from patients seen in other locations;
C. difﬁcile strain types 2 and 10 were also common (10%
each).
DISCUSSION
This study documents a high incidence of CDI (37 of 150,
24.7%) inpatients admitted to our BMTunit for hematopoietic
stem cell transplantation. Based onprior clustering of cases in
certain months, cross-transmission due to environmental
and/or health care worker contamination from active CDI
cases in the unit was initially suspected as the major source.
However, in this prospective study using admission C. difﬁcile
screens, it was found that at least 10.7% of patients admitted
for HSCT were colonized, nearly all of whom developed CDI.Figure 3. Comparison of Clostridium difﬁcile strain types identiﬁed by multi-
locus sequence typing from patients in the bone marrow transplantation
(BMT) unit versus other locations. Closed bars, BMT strains. Open bars, strains
from other locations.
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of 22 CDI patients identiﬁed 15 different strain types and 1
potential cross-transmission event among them.
Notably, CDC identiﬁed by a 2-step assay using an EIA
screen was a major risk factor for CDI (14 of 16 versus 23 of
134; P< .01). The onset of CDI was also signiﬁcantly earlier in
CDC patients than in patients with negative screens (0 versus
11 days after HSCT; P< .001). However, thismay partly reﬂect
the fact that most patients developed diarrhea early after
admission as a result of their transplantation regimens.
Although this is one of the ﬁrst studies to report the rate
of CDC in patients undergoing HSCT, the true prevalence of
CDC in this patient population was likely underestimated by
the 2-step C. difﬁcile assay using an EIA screen rather than a
direct cytotoxin or molecular assay on all specimens. Most
studies of CDC have used amore sensitive toxigenic C. difﬁcile
culture, or more recently, a direct toxin PCR assay. In a large
study by Loo et al., 4.4% of 4143 hospitalized patients had
CDC on admission using a toxigenic C. difﬁcile culture
(excluding patients with prior CDI within 8 weeks) [13]. In
comparison, Leekha et al. found that 9.7% of 320 asymp-
tomatic hospitalized patients at a tertiary care hospital were
positive for toxigenic C. difﬁcile using a PCR assay performed
on a ﬁrst stool specimen after admission [14].
There was no difference in the incidence of CDI between
patients receiving autologous and allogeneic HSCTs in this
study. In contrast, Triﬁlio et al. found that CDI occurred
signiﬁcantly more often in allogeneic recipients (14.5%)
compared with autologous HSCT recipients (8.5%) [15]. Both
CDC and CDI were signiﬁcantly more common in younger
patients undergoing allogeneic HSCTs in the current study, in
contrast to the general population, in which older age is an
established risk factor for CDI [16,17]. Further review sug-
gests that most of the younger patients in this study with
CDC and CDI were more intensively treated with chemo-
therapy before admission and had more prolonged prior
hospitalizations and antibiotic exposure.
The overall incidence of CDI (24.7%) within 100 days after
HSCT was higher than in prior studies in HSCT recipients
(range, 4% to 20%) [15]. It is difﬁcult, however, to compare
studies among different BMT programs, given the many
variables in patient population, transplantation types, and
conditioning regimens. Moreover, this patient population
has multiple other reasons to develop diarrhea, including
the toxicity of the conditioning regimens, antibiotic-
associated diarrhea, and GVHD. In particular, a unique
aspect of our transplantation programwas the use of DLIs in
the majority of the allogeneic HSCT recipients (72.8%). DLIs
frequently cause a systemic inﬂammatory response syn-
drome associated with diarrhea, which can be difﬁcult to
distinguish from CDI.
This study identiﬁed an early onset of CDI in both autol-
ogous and allogeneic HSCT recipients with a median of
3.5 days after HSCT. In contrast, in the large study of 999
HSCT recipients by Alonso et al., there was a signiﬁcant delay
in the onset of CDI among allogeneic recipients compared
with autologous recipients (median, 33 versus 6.5 days after
HSCT, respectively) [4]. The early onset of CDI in allogeneic
HSCT recipients in this study may partly be related to the
fever and diarrhea associated with the use of DLI and other
transplantation-related toxicities, which may be difﬁcult to
distinguish from CDI. Additionally, although there was no
standardized protocol for testing patients other than
admission screens, the fact that there was an ongoing study
may have led to more frequent C. difﬁcile testing.Surprisingly, there were no differences in outcomes be-
tween patients with and without CDI, and the CDI recurrence
rate was lower than expected. This may partly reﬂect early
identiﬁcation and prompt treatment of CDI cases. Addition-
ally, although all of these patients were treated for CDI, it is
likely that some of the patients with positive toxin assays
developed diarrhea because of other causes, as described
above. C. difﬁcile toxin EIA assays may also be associated with
false-positive test results [18,19]. Finally, some outpatient
recurrences may not have been captured in this retrospective
review.
C. difﬁcileMLSTanalysis on toxin-positive stool specimens
from 22 BMT unit patients revealed multiple different strain
types (15 types). Analysis of cases with the same strains
identiﬁed 1 potential unit-based cross transmission event
among this subset of patients in a pair infected with strain
type 2. However, because strain type 2 was also the most
common strain identiﬁed in the unit (27.3%), it is possible
that the timing of the 2 cases was coincidental. In compari-
son, a large United Kingdom study, in which over
1200 C. difﬁcile specimens were analyzed by MLST, identiﬁed
potential ward-based transmission in 25% of cases [20]. In
that study, the NAP1 epidemic strain type 1 was the most
common pathogen identiﬁed (17.9%), followed by strain 2
(10.3%). The diversity of strain types in the BMT unit was
similar to that found among a panel of 39 randomly typed
toxin-positive specimens from patients in other locations,
except that there was a lower incidence of strain type 1
among the BMT unit patients compared with CDI patients in
other locations (4.5% versus 18% respectively, P ¼ .24).
There was a nonsigniﬁcant increase in the number of CDI
cases in the second year of the study, despite enhanced
infection control measures, which included universal
gowning and gloving, hand washing with soap and water
leaving patient rooms, and daily bleach cleaning of rooms.
This may partly reﬂect a change in the C. difﬁcile testing
method, ie, the clinical microbiology lab changed the second
step of the assay from a cytotoxin assay to a more sensitive
molecular toxin assay in the second year of the study.
Although there was also a cluster of cases in the third quarter
of 2012, 4 of the 5 strains types identiﬁed during this period
were unique.
There are several limitations inherent to this study. First,
the 2-step C. difﬁcile assay with an EIA screen used in this
study is less sensitive for the detection of low-level asymp-
tomatic colonization compared with a direct toxigenic
C. difﬁcile culture or C. difﬁcile toxin PCR [16,17]. Second, there
were multiple confounding causes of diarrhea in patients
undergoing HSCT, so that it was difﬁcult to distinguish be-
tween CDI and CDC. There was also potential inaccuracy
associated with a retrospective chart review, and data about
prior admissions to outside hospitals was not captured.
Additionally, this study may not have had the statistical po-
wer to identify other risk factors for CDC and CDI because of
the relatively small sample size.
Another major limitation of this investigation was that
only 52.4% (22 of 42 unique patients) of the toxin-positive
stool specimens from patients hospitalized in the BMT unit
were successfully typed by MLST. Therefore, cross-
transmission events may have been missed. Specimens
were stored at 20C for MLST, but stool samples from 11
cases were inadvertently not saved. The DNA extraction was
performed directly on whole stool specimens, rather than
ﬁrst isolating C. difﬁcile from the stool samples by culture,
because C. difﬁcile culture is labor-intensive and technically
J. Bruminhent et al. / Biol Blood Marrow Transplant 20 (2014) 1329e13341334challenging and is not routinely performed in most micro-
biology laboratories. Moreover, Grifﬁths et al. demonstrated
that theMLST protocol could be performed using whole stool
[7]. However, the typing success rate of MLST on whole stool
specimens from BMT unit patients was only 71% (22 of 31
specimens tested). The presence of multiple inhibitors in
whole stool may have reduced the sensitivity of the PCR
assays. Additionally, the recovery of C. difﬁcile DNAwas likely
adversely inﬂuenced by suboptimal storage of clinical spec-
imens before freezing and by repeated thawing and freezing
of stool samples.
In summary, this study describes a high incidence of CDI
among adult patients undergoing HSCT at a single institution
and identiﬁes admission CDC as a statistically signiﬁcant risk
factor. MLST analysis on 22 C. difﬁcile clinical specimens
identiﬁed 15 different strain types. Although only 1 potential
cross-transmission event was identiﬁed among the subset of
patients with typed strains, other cross-transmission events
may have been missed, as nearly one half of the specimens
were not typed. However, despite aggressive infection con-
trol interventions to reduce cross-transmission, there was no
reduction in CDI rates during the study period. Additional
studies are needed to help understand the impact of CDC in
this high-risk population to develop strategies to reduce CDI
rates after HSCT.
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